GV1001

Combination with Immune Checkpoint Inhibitors

Preclinical and early clinical investigations have explored combining GV1001 with immune checkpoint inhibitors (anti-PD-1, anti-CTLA-4). The rationale is that GV1001 primes tumor-specific T cells, while checkpoint inhibitors remove the immunosuppressive brakes that limit T-cell effector function within the tumor microenvironment. This combination strategy aims to overcome the limited efficacy seen when GV1001 was used as monotherapy in the TeloVac trial.

Clinical Research Protocols

• TeloVac Phase III (ISRCTN4382138): GV1001 0.56 mg intradermal injection on days 1, 3, 5, 8, 15, 22, then monthly; GM-CSF 75 mcg co-injection at each vaccination site; administered with gemcitabine 1000 mg/m2 IV + capecitabine 830 mg/m2 PO twice daily
• NSCLC Phase I/II: GV1001 dose escalation (0.07, 0.7, 2.8 mg intradermal) with GM-CSF 75 mcg; vaccination on days 1, 3, 5, 8, 15, 22 then monthly boosters
• Immune monitoring: IFN-gamma ELISPOT assay, proliferation assays, and DTH (delayed-type hypersensitivity) skin testing to assess GV1001-specific T-cell responses
• Combination protocols under investigation: GV1001 + anti-PD-1 (pembrolizumab/nivolumab) in pancreatic cancer and NSCLC settings

Immunological Mechanisms (Deep Dive)

HLA-promiscuous binding:

• GV1001 binds HLA-A2, HLA-A24, HLA-B7, HLA-B35, and multiple HLA-DR alleles
• This broad HLA binding profile enables immune responses in >95% of patients regardless of HLA type
• The 16-amino acid length accommodates both MHC class I (8-10 mer) and MHC class II (13-25 mer) binding motifs within the same peptide

T-cell response characteristics:

• CD4+ T-helper 1 (Th1) polarized responses predominate, characterized by IFN-gamma and TNF-alpha production
• CD8+ CTL responses demonstrate direct cytotoxicity against hTERT+ tumor cells through perforin/granzyme pathway
• Generation of central memory T cells (TCM) provides long-lasting anti-tumor surveillance
• T-cell receptor (TCR) repertoire analysis reveals oligoclonal expansion of GV1001-specific T cells

Tumor immune evasion and GV1001:

• Tumors may downregulate MHC class I to escape CTL recognition; GV1001-induced CD4+ T cells provide MHC-independent anti-tumor effects via cytokine release
• Telomerase downregulation as an escape mechanism is limited because telomerase is essential for tumor cell immortality
• Regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment may blunt vaccine responses, providing rationale for checkpoint inhibitor combinations

Ongoing & Future Research

• GV1001 combination trials with immune checkpoint inhibitors in pancreatic cancer and NSCLC
• Investigation of GV1001 as maintenance therapy after first-line chemotherapy response
• Exploration of neoantigen-based personalized vaccines combined with GV1001 as a universal tumor antigen component
• GV1001 in non-oncology applications: Alzheimer's disease (anti-inflammatory properties), ischemia-reperfusion injury, pulmonary fibrosis
• Development of next-generation telomerase vaccines incorporating multiple hTERT epitopes and novel adjuvant platforms (TLR agonists, nanoparticle delivery)
• Biomarker-driven patient selection strategies to identify patients most likely to mount robust immune responses

Phase I/II Trials in NSCLC

Brunsvig PF et al. (2006) reported the first clinical trial of GV1001 in 26 patients with advanced NSCLC. GV1001 was administered intradermally with GM-CSF as adjuvant. Immune responses were detected in 11 of 24 evaluable patients (46%). GV1001-specific T-cell responses correlated with prolonged survival: immune responders had a median survival of 19 months compared to 3.5 months for non-responders. No grade 3/4 toxicities were attributed to the vaccine. Published in Cancer Immunol Immunother 55(12):1553-1564.

Phase III TeloVac Trial in Pancreatic Cancer

Middleton GW et al. (2014) conducted the pivotal Phase III TeloVac trial, randomizing 1062 patients with locally advanced or metastatic pancreatic cancer to three arms: (1) gemcitabine/capecitabine chemotherapy alone, (2) chemotherapy followed by sequential GV1001 vaccination, or (3) concurrent chemotherapy with GV1001 vaccination. The primary endpoint of overall survival was not met: median OS was 7.9 months in the chemotherapy-alone arm versus 6.9 months (sequential) and 8.4 months (concurrent). The concurrent arm showed a non-significant trend toward improved survival. Immune response rates were lower than expected (25%), potentially due to immunosuppression from concurrent chemotherapy. Published in Br J Cancer 108(12):2394-2401.

Phase I/II in Hepatocellular Carcinoma

Greten TF et al. (2010) evaluated GV1001 in patients with advanced hepatocellular carcinoma (HCC). The study demonstrated that GV1001 vaccination could induce hTERT-specific T-cell responses in HCC patients, a population with significant baseline immunosuppression. Immune responders showed trends toward improved clinical outcomes, supporting the immunogenicity of GV1001 even in immunologically challenging tumor microenvironments. Published in J Hepatol 52(4):583-589.

Immune Response Characterization

Bernhardt SL et al. (2006) characterized the immune responses induced by GV1001 in detail, demonstrating that the peptide elicits both CD4+ T-helper and CD8+ CTL responses. Immune monitoring by ELISPOT assay revealed IFN-gamma-producing T cells specific for GV1001 in responding patients. T-cell clones derived from vaccinated patients demonstrated direct cytotoxicity against telomerase-positive tumor cell lines in vitro, confirming the functional relevance of vaccine-induced immunity. Published in Cancer Immunol Immunother 55(12):1564-1574.

Pancreatic Cancer — TeloVac Phase 3 Trial

Middleton G et al. (2014) conducted the definitive Phase 3 trial of GV1001 in pancreatic cancer. The TeloVac trial randomized 1062 patients with locally advanced or metastatic pancreatic cancer to receive gemcitabine/capecitabine alone, concurrent GV1001 with chemotherapy, or sequential GV1001 after chemotherapy. The primary endpoint — overall survival — was not met in the intent-to-treat analysis (median OS: 6.9 months control vs. 6.4 months concurrent GV1001 vs. 8.4 months sequential GV1001). However, the critical secondary finding was that patients who developed GV1001-specific immune responses (approximately 50% of vaccinated patients) had significantly better survival than non-responders. Published in Lancet Oncology, this trial remains the largest randomized study of a telomerase peptide vaccine.

Hepatocellular Carcinoma

GV1001 has been investigated in early-phase trials for hepatocellular carcinoma (HCC), where telomerase is reactivated in the majority of tumors during hepatocarcinogenesis. The peptide showed immunogenicity in HCC patients, and GV1001-specific T cell responses correlated with disease stabilization in a subset of patients. GemVax & KAEL continues development of GV1001 for HCC in Asian markets.

Alzheimer's Disease — Clinical Evidence

Park HH et al. (2022) reported results from a randomized, double-blind, placebo-controlled clinical trial of GV1001 in patients with moderate-to-severe Alzheimer's disease conducted in South Korea. Patients receiving GV1001 showed significant improvement on the Severe Impairment Battery (SIB) cognitive scale compared to placebo. The treatment was well-tolerated with no serious adverse events attributed to GV1001. Biomarker analysis suggested reduced neuroinflammation markers in the GV1001 group. This study represents the first clinical evidence that a telomerase-derived peptide can improve cognition in a neurodegenerative disease through mechanisms independent of cancer immunity.

Anti-Inflammatory Mechanism

Kim BK et al. (2023) elucidated the molecular mechanism underlying GV1001's anti-inflammatory effects. Using vascular endothelial cells and macrophages, they demonstrated that GV1001 enters cells via its amphipathic structure, binds HSP90 and HSP70 in the cytoplasm, and prevents HSP-mediated stabilization of the IKK complex. This results in reduced IkBalpha phosphorylation and degradation, preventing NF-kB p65 nuclear translocation and suppressing transcription of pro-inflammatory cytokines. The study showed dose-dependent reduction of TNF-alpha (60-80%), IL-6 (50-70%), and IL-1beta (40-60%) in LPS-stimulated cells.

Non-Small Cell Lung Cancer

Brunsvig PF et al. (2006) reported Phase I/II results of GV1001 in 26 patients with advanced NSCLC. GV1001 (0.1-0.9 mg) was administered intradermally with GM-CSF at days 1, 3, 5, 8, 15, 22, and monthly thereafter. Immune responses were detected in 11 of 24 evaluable patients (46%). Immune responders showed a non-significant trend toward improved survival. The safety profile was favorable, with injection site reactions as the most common adverse event. No dose-limiting toxicities were observed.